Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Skin Manifestations and Treatment during the COVID-19 Pandemic
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Skin Manifestations and Treatment during the COVID-19 Pandemic

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 16383

Special Issue Editors

Prof. Dr. Gabriella Fabbrocini

E-Mail Website
Guest Editor
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Napoly, Italy
Interests: acne; inflammatory skin diseases (atopic dermatitis; hidradenitis; psoriasis); dermoscopy; melanoma; photodermatology and alopecia; dermocosmetological care of chemotherapy skin reaction “corpo ritrovato”
Special Issues, Collections and Topics in MDPI journals
Dr. Claudio Marasca

E-Mail Website
Guest Editor
“Antonio Cardarelli” National Hospital of Naples, Naples, Italy
Interests: dermatology; hidradenitis; psoriasis; biologic drugs; dermoscopy; ultrasonography; teledermatology; melanoma; skin tumors; basal cell carcinoma; wound care; inflammatory skin disease
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The coronavirus disease 2019 (COVID-19) outbreak has revolutionized the world and, at the same time, medicine itself. The scientific world has focused on every aspect of this viral infection, trying to identify its numerous peculiarities in order to improve diagnostic skills, therapeutic options, and management of patients. Dermatology became soon involved, because of the potential of Covid-19 to cause rashes, presenting particular characteristics in relation to the age of the affected patients. The last months have seen a sharp progress in medical sciences such as telemedicine, and dermatology, as an iconographic discipline, has been the leader in the development and growth of this practice. Other aspects of COVID-19 related to dermatology include the possible risk of infection ascribable to the use of biotechnological drugs, increasingly widespread in the management of patients suffering from chronic skin diseases, such as psoriasis, atopic dermatitis, and hidradenitis suppurativa.

Prof. Gabriella Fabbrocini
Dr. Claudio Marasca
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19
  • skin rash due to COVID
  • telemedicine
  • teledermatology
  • biologic drugs

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

4 pages, 459 KiB  
Article
Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience
by Nevena Skroza, Nicoletta Bernardini, Ersilia Tolino, Ilaria Proietti, Alessandra Mambrin, Anna Marchesiello, Federica Marraffa, Giovanni Rossi, Salvatore Volpe and Concetta Potenza
J. Clin. Med. 2021, 10(15), 3355; https://doi.org/10.3390/jcm10153355 - 29 Jul 2021
Cited by 16 | Viewed by 2680
Abstract
Since all clinical trials conducted during the development of anti-COVID-19 vaccines have adopted among the exclusion criteria the presence of immunodepression or immunomodulating therapy, to date, the effects of vaccination against the new coronavirus 2 in people under such conditions have yet to [...] Read more.
Since all clinical trials conducted during the development of anti-COVID-19 vaccines have adopted among the exclusion criteria the presence of immunodepression or immunomodulating therapy, to date, the effects of vaccination against the new coronavirus 2 in people under such conditions have yet to be clearly defined. The primary objective of the study is to assess the safety of treatment with biotechnological drugs in patients suffering from moderate–severe psoriasis and subjected to the prophylactic vaccination against SARS-Cov-2. Additionally, the secondary objective of the research is to investigate the existence of a possible impact of anti-COVID-19 vaccination on the natural chronic-relapsing course and the severity of the psoriatic disease. The study included 436 patients with moderate–severe psoriasis, both male and female, in treatment with biologics. The data were collected using the direct interview method. A reduction of 74.13% of average Psoriasis Area Severity Index (PASI )compared to baseline (T0) was found in all subjects; this does not differ significantly from the group that underwent vaccination (73.4%). Moreover; at the end of the study, neither mild nor severe adverse events (ADR) were observed among them. In conclusion, biotechnological drugs used in the management of patients with moderate–severe psoriasis demonstrate a high safety profile also in subjects immunized against SARS-Cov-2. Full article
(This article belongs to the Special Issue Skin Manifestations and Treatment during the COVID-19 Pandemic)
►▼ Show Figures

Figure 1

Review

Jump to: Research

20 pages, 399 KiB  
Review
Treatment of Moderate to Severe Psoriasis during the COVID-19 Pandemic: Lessons Learned and Opportunities
by Anna Campanati, Federico Diotallevi, Emanuela Martina, Giulia Radi and Annamaria Offidani
J. Clin. Med. 2022, 11(9), 2422; https://doi.org/10.3390/jcm11092422 - 26 Apr 2022
Cited by 2 | Viewed by 2655
Abstract
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, clinicians have been overwhelmed by questions beyond the SARS-CoV-2 infection itself. In dermatology practice, clinicians have been facing difficulties concerning therapeutic management of chronic immune-mediated skin disease, above all psoriasis. Major challenges arisen [...] Read more.
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, clinicians have been overwhelmed by questions beyond the SARS-CoV-2 infection itself. In dermatology practice, clinicians have been facing difficulties concerning therapeutic management of chronic immune-mediated skin disease, above all psoriasis. Major challenges arisen were to understand the role of immunosuppression or immunomodulation on COVID-19 evolution, the benefit/risk ratio related to discontinuation or modification of ongoing treatment, and the appropriateness of initiating new treatments, the optimization of timing in vaccination administration to patients under immunomodulatory treatments, and finally how to find new strategy of patients’ management through remote assistance. In this comprehensive review, we present the current evidence about the course and management of psoriasis during the COVID-19 pandemic. The general message from dermatologists was that data did not suggest that having PSO or its treatment significantly increased risk of SARS-CoV-2 infection or more severe COVID-19 course, the vaccination is highly recommended in all psoriatic patients, beyond ongoing treatment, and that the telehealth experience was a success overall. Full article
(This article belongs to the Special Issue Skin Manifestations and Treatment during the COVID-19 Pandemic)
►▼ Show Figures

Figure 1

20 pages, 540 KiB  
Review
Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications
by Claudio Marasca, Maria Carmela Annunziata, Elisa Camela, Adriana Di Guida, Luigi Fornaro, Matteo Megna, Maddalena Napolitano, Cataldo Patruno, Luca Potestio and Gabriella Fabbrocini
J. Clin. Med. 2022, 11(6), 1511; https://doi.org/10.3390/jcm11061511 - 10 Mar 2022
Cited by 40 | Viewed by 3539
Abstract
Background: The most frequent inflammatory skin diseases are psoriasis, atopic dermatitis, hidradenitis suppurativa, and acne. Their management is challenging for dermatologists since their relapsing chronic clinical course is associated with a great impact on quality of life. Nevertheless, the recent introduction of novel [...] Read more.
Background: The most frequent inflammatory skin diseases are psoriasis, atopic dermatitis, hidradenitis suppurativa, and acne. Their management is challenging for dermatologists since their relapsing chronic clinical course is associated with a great impact on quality of life. Nevertheless, the recent introduction of novel therapies, such as biological drugs and small molecules has been changing the history of these diseases. Methods: A systematic review of the scientific literature of case reports, case series, epidemiological studies, reviews, and systematic reviews regarding teledermatology and inflammatory skin disease. Studies were identified, screened, and extracted for relevant data following the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. Results: A total of 69 cases articles were included in the review. Conclusions: As we have shown in the review, several experiences of teledermatology for patients affected by inflammatory skin diseases have been demonstrated to increase due to clinical access to hospital and specialized health care services, allowing better access to specialized dermatology care for people living in remote areas, and saving costs and money with health care. Full article
(This article belongs to the Special Issue Skin Manifestations and Treatment during the COVID-19 Pandemic)
►▼ Show Figures

Figure 1

12 pages, 653 KiB  
Review
Erythema Migrans-like COVID Vaccine Arm: A Literature Review
by Gaia Fasano, Luigi Bennardo, Silvana Ruffolo, Maria Passante, Azzurra Gaia Ambrosio, Maddalena Napolitano, Eugenio Provenzano, Steven Paul Nisticò and Cataldo Patruno
J. Clin. Med. 2022, 11(3), 797; https://doi.org/10.3390/jcm11030797 - 1 Feb 2022
Cited by 5 | Viewed by 3397
Abstract
COVID Vaccine Arm (CVA) is an adverse drug reaction from mRNA vaccine for SARS-CoV-2. CVA is characterized by erythema and edema on the vaccination site (usually deltoid area) that appears from 5 to 10 days after vaccination and is sometimes associated with itching [...] Read more.
COVID Vaccine Arm (CVA) is an adverse drug reaction from mRNA vaccine for SARS-CoV-2. CVA is characterized by erythema and edema on the vaccination site (usually deltoid area) that appears from 5 to 10 days after vaccination and is sometimes associated with itching or pain. The exact etiology of CVA is still unclear, but delayed hypersensitivity against an excipient seems to play an essential role in the pathogenesis of the disease. This work performs a systematic literature review on CVA using three different databases containing articles published until 10 November 2021. The literature review includes eight papers reporting single cases or case series of CVA. Moreover, it also addresses, other cutaneous reactions following COVID 19 vaccinations as well as possible differential diagnosis. CVA migrans-like erythema is characterized by a ring-shaped rash in the injection area, which appears some days after the injection and disappears in about 10 days. This reaction may appear more rapidly in subsequent doses. Full article
(This article belongs to the Special Issue Skin Manifestations and Treatment during the COVID-19 Pandemic)
►▼ Show Figures

Figure 1

13 pages, 1067 KiB  
Review
Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic
by Elia Rosi, Maria Thais Fastame, Antonella Di Cesare, Gianmarco Silvi, Nicola Pimpinelli and Francesca Prignano
J. Clin. Med. 2021, 10(24), 5841; https://doi.org/10.3390/jcm10245841 - 13 Dec 2021
Cited by 3 | Viewed by 2593
Abstract
The Coronavirus Disease 2019 (COVID-19) pandemic, a global public health emergency, has changed dermatology practice and daily routine in just under two years. Much has been written in the literature about COVID-19-associated skin manifestations. Nevertheless, much less has been written regarding skin manifestations [...] Read more.
The Coronavirus Disease 2019 (COVID-19) pandemic, a global public health emergency, has changed dermatology practice and daily routine in just under two years. Much has been written in the literature about COVID-19-associated skin manifestations. Nevertheless, much less has been written regarding skin manifestations in patients affected by severe immune-mediated skin diseases, e.g., psoriasis and hidradenitis suppurativa, undergoing biological treatment during the COVID-19 outbreak. Thus, the aim of this article is to provide the reader with an overview of the cutaneous manifestations during the COVID-19 pandemic in this subset of patients. Full article
(This article belongs to the Special Issue Skin Manifestations and Treatment during the COVID-19 Pandemic)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop